Achilles Therapeutics Plc (ACHL)

[jondoeuk]

PELEUS was designed and trained using TRACERx data. That was longitudinal across five years from over 780 NSCLC patients (deep sequencing, multi-region and multi-time points, with over 3,000 tumour samples). After DNA seq they use it to compare tumour DNA to healthy DNA and select clonal sequences for use in dendritic cell co-culture.

As for VELOS, process two generates products with increased clonal neoantigen reactivities, as well as higher doses.